Table 1.
Current phase II/III clinical trials of GBM vaccines.
| Antigen Target | Antigen Platform | Antigen Classification | Phase | Status | NCT Identifier | |
|---|---|---|---|---|---|---|
| Autologous GSC lysate | Autologous glioma stem-like cell antigens | DC | Personalized antigen | I/II | Completed | NCT00846456 |
| Autologous tumour and GSC lysate | DC | TSA + TAA | II/III | Unknown | NCT01759810 | |
| Autologous tumour lysate | Autologous tumour antigens | Uncertain | Personalized antigen | II | Completed | NCT00014573 |
| Autologous tumour lysate | Peptide | Personalized antigen | II/III | Not yet recruiting | NCT05685004 | |
| Autologous tumour lysate | DC | Personalized antigen | I/II | Recruiting | NCT03879512 | |
| Autologous tumour lysate | DC | Personalized antigen | I/II | Recruiting | NCT04801147 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Active | NCT01204684 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Active | NCT03400917 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Completed | NCT00323115 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Completed | NCT01213407 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Completed | NCT00576537 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Completed | NCT01006044 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Recruiting | NCT04523688 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Recruiting | NCT04115761 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Recruiting | NCT03395587 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Unknown | NCT02772094 | |
| Autologous tumour lysate | DC | Personalized antigen | II | Withdrawn | NCT03014804 | |
| Autologous tumour lysate | DC | Personalized antigen | III | Active | NCT00045968 | |
| Autologous tumour lysate | DC | Personalized antigen | III | Not yet recruiting | NCT05100641 | |
| Autologous tumour lysate | DC | Personalized antigen | III | Unknown | NCT04277221 | |
| EGFRvIII | EGFRvIII | Peptide | TSA | II | Completed | NCT00643097 |
| EGFRvIII | Peptide | TSA | II | Completed | NCT00458601 | |
| EGFRvIII | Peptide | TSA | III | Completed | NCT01480479 | |
| EGFRvIII, IL13Rα2, EphA2, Her2/neu, YKL-40 | Peptide | TSA + TAA | II | Withdrawn | NCT02754362 | |
| GSC Antigen | GSC antigens | DC | TSA + TAA | II | Recruiting | NCT04888611 |
| GSC antigens | DC | TSA + TAA | II | Unknown | NCT01567202 | |
| GSC antigens, survivin and hTERT | DC | TSA + TAA | II/III | Active | NCT03548571 | |
| Survivin | SurVaxM (survivin) | Peptide | TAA | II | Active | NCT02455557 |
| SurVaxM (survivin) | Peptide | TAA | II | Recruiting | NCT05163080 | |
| WT1 | Wilms’ tumour protein 1 (WT1) | Peptide | TAA | III | Completed | NCT03149003 |
| Wilms’ tumour protein 1 (WT1) | DC | TAA | I/II | Completed | NCT01291420 | |
| Wilms’ tumor protein 1 (WT1) | DC | TAA | I/II | Recruiting | NCT02649582 | |
| HSPPC-96 | HSPPC-96 | Peptide | TAA | I/II | Completed | NCT00293423 |
| HSPPC-96 | Peptide | TAA | I/II | Recruiting | NCT03650257 | |
| HSPPC-96 | Peptide | TAA | II | Completed | NCT00905060 | |
| HSPPC-96 | Peptide | TAA | II | Completed | NCT03018288 | |
| HSPPC-96 | Peptide | TAA | II | Terminated | NCT01814813 | |
| Combined TAA | ICT-107 (MAGE-1, HER-2, AIM-2, TRP-2, gp100, IL13Rα2) | DC | TAA | II | Completed | NCT01280552 |
| IMA950 (BCAN, CSPG4, FABP7, IGF2BP3, NRCAM, NLGN4X, PTPRZ1, TNC, survivin, c-met) | Peptide | TAA | I/II | Active | NCT03665545 | |
| IMA950 (BCAN, CSPG4, FABP7, IGF2BP3, NRCAM, NLGN4X, PTPRZ2, TNC, survivin, c-met) | Peptide | TAA | I/II | Completed | NCT01920191 | |
| SL-701 (survivin, IL-13Rα2, and EphA2) | Peptide | TAA | I/II | Completed | NCT02078648 | |
| CMV | CMV (gB and pp65) | Virus vector | Pathogen-derived antigen | I/II | Recruiting | NCT03382977 |
| CMV (pp65) | DC | Pathogen-derived antigen | II | Active | NCT02465268 | |
| CMV (pp65) | DC | Pathogen-derived antigen | II | Active | NCT03688178 | |
| CMV (pp65) | DC | Pathogen-derived antigen | II | Completed | NCT02366728 | |
| CMV (pp65) | DC | Pathogen-derived antigen | II | Terminated | NCT03927222 | |
| Other | Dendritic and Glioma Cells Fusion vaccine | DC | Personalized antigen | I/II | Recruiting | NCT04388033 |
| Telomerase (TERT)-derived helper peptides | Peptide | TAA | II | Active | NCT04280848 | |
| VXM01 (VEGFR2) | Attenuated Salmonella bacteria | TAA | I/II | Active | NCT03750071 | |
| EO2401 (IL13Rα2, BIRC5, FOXM1) | Peptide | TAA | I/II | Active | NCT04116658 |